Nurse-led group consultation intervention reduces depressive symptoms in men with localised prostate cancer: a cluster randomised controlled trial

Schofield, Penelope; Gough, Karla; Lotfi-Jam, Kerryann; Bergin, Rebecca; Ugalde, Anna; Dudgeon, Paul; Crellin, Wallace; Schubach, Kathryn; Foroudi, Farshard; Tai, Keen Hun; Duchesne, Gillian; Sanson-Fisher, Rob; Aranda, Sanchia

doi:10.1186/s12885-016-2687-1

Table 4 Mean change from baseline and effect size at the end of radiotherapy and 6 months post-radiotherapy

From: Nurse-led group consultation intervention reduces depressive symptoms in men with localised prostate cancer: a cluster randomised controlled trial

		Usual care			Intervention			Between-groups difference	95 % CI	Effect size
		Mean change from baseline	95 % CI	Effect size	Mean change from baseline	95 % CI	Effect size	Between-groups difference	95 % CI	Effect size
End of radiotherapy
HADS	Anxiety	−0.7	−1.2, −0.3	0.21	−1.0	−1.4, −0.6	0.29	−0.2	−0.8, 0.4	0.09
HADS	Depression	0.6	0.3, 0.9	0.21	−0.2	−0.6, 0.1	0.07	−0.8	−1.2, −0.3	0.37
DT		0.1	−0.3, 0.5	0.05	−0.3	−0.7, 0.2	0.12	−0.4	−0.9, 0.2	0.15
EPIC-26	Urinary	−11.0	−13.4, −8.6	0.68	−9.2	−11.5, −6.9	0.62	1.8	−1.5, 5.1	0.12
	Bowel	−15.7	−18.4, −12.9	1.34	−12.8	−15.8, −9.8	0.99	2.9	−1.1, 6.9	0.16
	Sexual	−5.2	−7.9, −2.5	0.18	−2.8	−5.5, −0.2	0.11	2.4	−1.4, 6.1	0.14
	Hormonal	−1.8	−4.0, 0.3	0.10	0.0	−2.2, 2.2	0.00	1.9	−1.2, 4.9	0.14
SCNS-SF34-R	Physical & daily living	6.0	3.0, 9.1	0.27	6.8	4.0, 9.7	0.37	0.8	−3.3, 5.0	0.04
	Psychological	−4.1	−6.9, −1.3	0.20	−6.7	−9.4, −4.0	0.32	−2.6	−6.5, 1.3	0.15
	Sexuality	−3.8	−7.8, 0.2	0.13	−4.9	−9.3, −0.5	0.17	−1.1	−7.0, 4.8	0.04
	Patient care and support	0.2	−2.5, 2.9	0.01	−0.8	−3.9, 2.3	0.05	−1.0	−5.1, 3.1	0.05
	Health system & information	−6.9	−11.0, −2.9	0.23	−7.6	−12.4, −2.8	0.26	−0.7	−6.9, 5.6	0.02
CaTS	Sensory/psychological	−0.6	−0.7, −0.5	0.64	−0.7	−0.8, −0.5	0.72	−0.1	−0.3, 0.1	0.10
CaTS	Procedural	−0.7	−0.9, −0.6	0.71	−1.0	−1.1, −0.8	0.86	−0.2	−0.5, −0.02	0.24
6 months post-radiotherapy
HADS	Anxiety	−0.6	−1.1, −0.2	0.18	−0.6	−1.1, −0.1	0.18	0.0	−0.7, 0.7	0.01
HADS	Depression	0.4	0.04, 0.8	0.16	0.1	−0.3, 0.5	0.04	−0.3	−0.9, 0.2	0.14
DT		−0.3	−0.6, 0.04	0.14	−0.5	−0.8, −0.2	0.21	−0.2	−0.7, 0.3	0.10
EPIC-26	Urinary	−1.0	−2.9, 0.9	0.06	−2.2	−4.5, 0.1	0.15	−1.2	−4.2, 1.8	0.09
	Bowel	−6.8	−9.4, −4.3	0.55	−6.2	−8.5, −3.9	0.57	0.6	−2.8, 4.1	0.04
	Sexual	−4.4	−8.0, −0.9	0.15	−2.1	−5.1, 0.9	0.08	2.3	−2.4, 7.1	0.11
	Hormonal	−0.8	−3.2, 1.6	0.05	1.3	−1.3, 4.0	0.07	2.2	−1.4, 5.7	0.14
SCNS-SF34-R	Physical & daily living	1.7	−1.4, 4.8	0.07	3.4	0.7, 6.1	0.19	1.8	−2.3, 5.9	0.10
	Psychological	−7.2	−10.2, −4.3	0.35	−8.0	−10.8, −5.3	0.39	−0.8	−4.9, 3.3	0.04
	Sexuality	0.0	−4.6, 4.5	0.00	−1.2	−5.5, 3.1	0.04	−1.2	−7.4, 5.1	0.04
	Patient care and support	−3.5	−6.1, −1.0	0.20	−1.7	−4.9, 1.5	0.10	1.8	−2.3, 5.9	0.10
	Health system & information	−10.9	−14.9, −7.0	0.37	−13.4	−17.8, −9.0	0.46	−2.5	−8.4, 3.5	0.09

Effect sizes for changes from baseline = (Mean change from baseline/standard deviation at baseline)
Effect sizes for between-groups differences = ((Intervention Mean change from baseline) – (Usual Care Mean change from baseline)) / pooled standard deviation for change. For HADS, DT, SCNS-SF34-R and CaTS, a score decrease reflects improvement; as such, between-groups differences with a negative sign indicate a greater improvement (or lesser deterioration) among intervention participants. For EPIC-26, a score increase reflects improvement; as such, between-groups differences with a positive sign indicate a greater improvement (or lesser deterioration) among intervention participants

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us